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Immunohistochemical evaluation of the effects of nebivolol on
intimal hyperplasia following endothelial injury
İlker AKAR1, Ali RAHMAN1, M. Cengiz ÇOLAK2, Bilal ÜSTÜNDAĞ3, İbrahim Hanifi ÖZERCAN4,
Ayhan UYSAL1

Aim: Intimal hyperplasia is a vascular remodeling process. It is a clinical problem that forms in the vascular wall as a result
of smooth muscle cell migration, proliferation, and extracellular matrix accumulation. In this study we examined the
immunohistochemical evaluation of the effects of nebivolol on intimal hyperplasia in damaged endothelial tissue.
Materials and methods: The study was conducted using 21 rabbits equally divided into 3 groups: control, solvent, and
nebivolol. The rabbits in the control group only underwent balloon injury of the abdominal aorta. The rabbits in the
solvent group and nebivolol group underwent balloon injury and were treated with solvent and nebivolol intraperitoneally
during the study. At the end of the study, the abdominal aortas were harvested. The intimal and medial areas were
measured and the intima/media ratios were calculated. Tissue nitric oxide levels were determined and
immunohistochemical findings were evaluated.
Results: Statistically there were no differences between the control and solvent groups with respect to the intimal and
medial areas, intima/media ratios, or the tissue nitric oxide (NO) levels. The neointimal thickening was significantly less
in the nebivolol group than in the control and solvent groups (P < 0.001). Intima/media ratio was decreased in the
nebivolol group (P < 0.001). Tissue nitric oxide levels were greater in the nebivolol group than in the control and solvent
groups (P < 0.01). Immunohistochemical data in the nebivolol group were significantly lower as compared with the other
groups (P < 0.05).
Conclusion: Nebivolol may be a useful agent in early restenosis after vascular reconstructive procedures.
Key words: Intimal hyperplasia, nitric oxide, nebivolol

Endotel hasarı sonrası oluşan intimal hiperplazi üzerine nebivololün etkilerinin
immünohistokimyasal değerlendirilmesi
Amaç: İntimal hiperplazi bir vasküler remodeling sürecidir. Bu vasküler duvarda düz kas migasyonu, proliferasyonu ve
ekstrasellüler matriks birikimi sonucu oluşan klinik bir problemdir. Bu çalışmada hasarlanmış endotel dokusunda oluşan
intimal hiperplazi üzerine nebivololün etkilerinin immünohistokimyasal değerlendirilmesi araştırdık.
Yöntem ve gereç: Çalışma, kontrol, solvent ve nebivolol şeklinde eşit 3 guruba ayrılan toplam 21 tavşan üzerinde
gerçekleştirildi. Kontrol grubundaki tavşanların abdominal aortalarına sadece balon ile hasar uygulandı. Solvent ve
nebivolol grubundaki tavşanlara balon hasarı uygulandı ve çalışma boyunca intraperitoneal solvent ve nebivolol verildi.
Çalışma sonunda, abdominal aort kesitlerinde intimal-medial alanları ölçülerek her bir kesitteki intima/media oranları
elde edildi. Doku nitrik oksit düzeyleri ölçüldü ve immünohisyokimyasal bulgular kaydedildi.
Bulgular: Kontrol ve solvent grupları arasında intimal, medial alanlar ile intima/media oranları ve doku NO düzeyleri
yönünden anlamlı fark bulunmadı. intimal alan artışı nebivolol grubunda kontrol ve solvent gruplarına göre anlamlı
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derecede az iken (P < 0,001), intima/media oranı da anlamlı olarak azaldı (P < 0,001). Doku NO düzeylerinde ise nebivolol
grubunda kontrol ve solvent gruplarına göre belirgin artış gözlendi (P < 0,01). Nebivolol grubundaki
immünohisyokimyasal veriler diğer gruplara göre belirgin olarak azalmıştı (P < 0,05).
Sonuç: Nebivolol kullanımının vasküler girişimlerden sonra erken restenoz gelişiminin engellenmesinde yararlı bir ajan
olabileceği düşüncesindeyiz.
Anahtar sözcükler: İntimal hiperplazi, nitrik oksit, nebivolol

Introduction
Arterial reconstructions can preserve the ischemia
with occlusive disease. The most important problems
reducing the success rate in arterial reconstructions
are thrombosis, intimal thickening, and luminal
narrowing that develop in the early and late periods
(1). Overall, intimal hyperplasia is held responsible in
approximately half of the early and late failures of
reconstruction. All forms of vascular interventions
cause damage to the vascular wall. Several authors
have focused on the “response to injury” hypothesis in
the development of intimal hyperplasia (2-4). The
development of intimal thickening is a part of the
physiological reparative response to induced damage
by the artery or graft (2,5). It has been documented
that several factors including endothelial damage,
platelet adherence and activation, mitogenic factors,
and smooth muscle proliferation and migration are
involved in development of this response (6).
The main event in the pathological intimal
hyperplasia developing in an injured artery is the
replication and migration of smooth muscle cells.
Macrophages and endothelial and smooth muscle
cells have been shown in cell culture studies to
synthesize and secrete several mitogenic factors (7,8).
Among these mitogenic factors, the most significant
ones are basic fibroblast growth factor (bFGF) and the
platelet-derived growth factor (PDGF). The
proliferation of smooth muscle cells in the media layer
and their migration to the intima are induced by these
2 factors (8). Basic FGF is stored in the endothelial
and smooth muscle cells. It is secreted in response to
endothelial damage, and stimulates proliferation of
smooth muscles in the media layer (9). On the other
hand, PDGF is secreted following activation of
platelets when they are adhered to and aggregated on
the damaged vascular surface. Though it is nominated
as platelet-derived, PDGF is also secreted by the
damaged endothelial and smooth muscle cells (9-11).
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The endothelial cells play critical roles in
maintenance of structural and functional
characteristics of the vascular wall (12). Nitric oxide
(NO) synthesized by the vascular endothelium is an
active compound with cytoprotective, regulatory, and
cytotoxic effects (13). It inhibits cellular activation in
the damaged endothelium in order to prevent
adhesion of monocytes and leukocytes to the
endothelium and prevents proliferation and migration
of vascular smooth muscle cells (14-19). Despite the
absence of in vivo studies evaluating the effects of
nebivolol on the development of intimal hyperplasia,
it has been shown to induce a direct vasodilator effect
via activation of endothelium-derived NO, which
plays a key role in regulation of the vascular tone (20).
Furthermore, Kakoki et al. have proposed that
nebivolol is a potent NO synthase stimulator (21).
Various pharmacological agents have been used
with the purpose of preventing the development of
intimal hyperplasia (5,16-18). In this study, we suggest
that nebivolol, which increases NO release from the
endothelium, would reduce intimal thickening. Also
we
studied
the
activity
of
nebivolol
immunohistochemically.
Materials and methods
A modification of the balloon catheter damage
model described by Hamon et al. (19) was used in this
study. Following approval of the ethics committee of
our faculty, the study was conducted on 21 healthy
adult white male New Zealand rabbits with a mean
age of 10 months and weighing 2400-2850 g. The
rabbits were obtained from the Veterinary Control
and Research Institute of the Ministry of Agriculture
in Elazığ. During the experiments, the rabbits were
kept in a sunlit room with air conditioning and the
room temperature was kept at 20 ± 2 ºC. Guide for the
Care and Use of the Laboratory Animals was
considered in all experiments carried out in this study.
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Groups
The rabbits were randomized into 3 groups of 7
rabbits each.
Group I (the Controls): The 7 rabbits in this
group did not receive nebivolol and only underwent
the procedure of vascular balloon catheter damage.
Group II (Solvent): Two days prior to the
procedure, the 7 rabbits in this group began to receive
the solvent, which was used for solving the active
compound, intraperitoneally at a volume equivalent
to that introduced in the nebivolol group, and the
administration of solvent continued for 28 days
following the procedure.
Group III (Nebivolol): The 7 rabbits in this group
intraperitoneally received nebivolol (Vasoxen, İ.E.
Ulagay, Turkish Republic) 2.5 mg/kg/day. The
administration of nebivolol was initiated 2 days prior
to and was continued until 28 days after the
procedure.
Preparation of the solution:
®
Nebivolol (Vasoxen , Berlin-Chemie, Menarini
Group, I. E. Ulagay, Germany), which is a lipophilic
agent, was obtained in the form of 5-mg tablets. The
solvent was prepared by mixing 80% distilled water
and 20% polyethylene glycol (Merck-Schuchardt,
Hohenbrunn, Germany) volumetrically. The
nebivolol tablets were powdered under sterile
conditions and then added to physiologic saline to
obtain a mixture that included 2.5 mg nebivolol per
milliliter.

Balloon catheter damage:
All rabbits were anesthetized using intramuscular
administration of ketamine hydrochloride (50 mg/kg
Ketalar®, Eczacıbaşı, Turkish Republic) and xylazine
hydrochloride (5 mg/kg, Rompun®, Bayer, Turkish
Republic). When needed, 1/3 of this dose was
repeated intramuscularly. Following anesthesia, an
intravenous line was inserted into the dorsal ear vein
of each rabbit for intravenous administration of
amoxicillin (Ampisina®, Mustafa Nevzat, Turkey) 50
mg/kg and heparin sulfate (Liquemine®, Roche,
Turkish Republic) 300 IU/kg 5 min prior to surgical
intervention. Then a longitudinal incision was made
under sterile conditions in the right pubic area for
mobilization of the right superficial femoral artery. A

vertical femoral arteriotomy was performed for
advancing a balloon angioplasty catheter (CordisEuropa, Holland) with a diameter of 2.5 mm and
length of 20 mm through the femoral artery in a
retrograde manner to the abdominal aorta. Under
fluoroscopy, the balloon of the angioplasty catheter
was inflated in the infrarenal abdominal aorta using a
balloon inflation device (Sedat SA, France) filled with
physiologic saline until a pressure of 8 atmospheres
was achieved, and was then retreated back to the
femoral artery. This procedure was performed 3 times
while rotating the catheter by 120º. In this way, intimal
damage was induced in the vascular wall. The catheter
was removed and the femoral artery was ligated at the
distal and proximal sides of the arteriotomy, followed
by suturing of the cutaneous incision.
Hemodynamic studies
The systolic, diastolic, and mean arterial pressures
and heart rates were measured in all rabbits at both
the beginning and the end of the experiment. The
right middle ear artery of each rabbit was cannulated
with a 24 G branula at the beginning and end of the
experiment for recordings using a portable monitor
(SC-600, Siemens, USA). In the treatment group, the
measurements at the end of the experiment were
made 24 h following the administration of the drug.
To prevent the rabbits being affected by
environmental factors, the hemodynamic evaluations
were made using the same anesthetic methods and
doses 20 min after the administration of the
anesthetic agents.
Preparation of the vascular specimens
At the end of the experiment, all rabbits were
anesthetized using the same method and the
abdominal aorta was freed via a subxyphoid
approach, and was cannulated with a 22 G branula. At
the same level, the vena cava inferior was cannulated
with a 22 G branula for draining the venous blood.
For preserving the in vivo dimensions of the arteries
until the histological examination, physiologic saline
was administered at a pressure of 80 mmHg through
the cannule within the aorta until clear fluid came
from the vena cava inferior. Then 10% formaldehyde
solution was infused through the same route at a
pressure of 80 mmHg for 20 min for fixation of the
vessels.
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The abdominal aorta was removed to the iliac
bifurcation without causing damage. A 3-cm-long
segment of the aorta distal to the level of the renal
artery was placed in a 10% formaldehyde solution for
referral to the pathology laboratory for histochemical
and immunohistochemical examinations, while the
segment until the iliac bifurcation was flushed with
physiologic saline and covered with aluminum foil for
referral to the biochemistry laboratory.
Biochemical examinations
The preparation of the NO fraction in the aortic
tissue was as follows: the weighed aortic tissues were
taken into homogenization tubes and then 9 mL of
Tris HCl buffer was added (0.2 mM; pH 7.5) for
expressing our results as μmol/g wet tissue.
The tissue specimens were homogenized at a speed
of 16,000 rpm. The homogenates were used for
determination of NO levels. In several previous
studies, the concentrations of endogenously
synthesized NO in tissues and body fluids were
determined by measuring nitrites and nitrates, as NO
soon is converted to first nitrite and then to nitrate at
the same site of synthesis. However, because
nonspecific reactions may take place in protein-rich
homogenates and solutions such as serum and
plasma, we deproteinized the homogenates prior to
measuring the nitrite and nitrate concentrations for
preventing these nonspecific reactions. Following
deproteinization, the amounts of nitrites and nitrates
in tissues were measured using the Griess reaction.
The total nitrite (nitrites + nitrates) concentration was
determined using the modified cadmium reduction
method. Copper-covered cadmium granules in
glycine buffer (pH 9.7) were incubated for 90 min
with the deproteinized specimen supernatant for
reduction of the nitrates. The nitrite produced was
then determined via spectrophotometric reading at a
wavelength of 545 nm of the pink color that emerged
by the reaction with sulphanilamide and the
corresponding N-naphthylethylene diamine (NNDA)
dinitrogenization
Immunohistochemical examination
From the paraffin blocks that had been prepared,
4-μm-thick slides were obtained, on which PDGF-β,
bFGF,
and
endothelin-1
had
been
immunohistochemically applied using the avidin56

biotin-peroxidase method. Then these 4-μm-thick
slides were deparaffinized and rehydrated, followed
by storing in 3% hydrogen peroxide for 5 min in order
to measure the endogenous peroxidase activity. Later,
they were rinsed with distilled water and kept in
citrate buffer (pH 6.0) at 650 microwaves (mw) for 5
min each for PDGF-β, bFGF, and endothelin-1. Ultra
V block was applied on the slides for 10 min. Then
PDGF-β (Neomarkers, Fremont, CA, USA), bFGF
(Chemicon International, USA), and endothelin-1
(Chamicon, Australia) antibodies were applied for 30
min in a bain-marie in a moist environment at a 37
°C. This was followed by rinsing with PBS 0.001 M
(pH 7.4), incubation with avidin-biotin peroxidase,
and staining with AEC chromogen. All slides were
contrast-stained with Mayer Hematoxylin and
mounted with ultramount medium.
The slides were scored from 0 to 3 according to the
density of staining in the intimal region as follows:
0

(0): no staining

+

(1): mild staining

++ (2): moderate staining, and
+++ (3): dense staining
Statistical Analyses
The statistical analyses were performed using SPSS
11.0 software. The data were expressed as the mean ±
standard deviation. The differences between groups
were analyzed using the Kruskal-Wallis H test, while
the Mann-Whitney U test was used for comparing the
2 groups. Analysis of data within groups prior to and
following intervention was made using the Wilcoxon
test. The pathological data obtained within groups
2
were analyzed using the chi-square (χ ) test when the
staining density was compared, and using the MannWhitney U test when the staining scores in the groups
were compared. P < 0.05 was regarded as statistically
significant.
Results
No statistically significant difference was found
between arterial pressure (MAP) values of the groups
prior to the experiment. At the end of the study, the
MAP values in the nebivolol group were significantly
lower as compared with both the control and solvent
groups (P < 0.01). The MAP value in the rabbits
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receiving nebivolol prior to the experiment was 82.57
± 4.35 mmHg, while it was reduced at the end of the
treatment period to 62.57 ± 3.86 mmHg (P < 0.01).
In contrast, no statistically significant difference
existed between the MAP values prior to and at the
end of the experiment in the control and the solvent
groups (P > 0.05). Likewise, no significant difference
was found between these 2 groups following the
experiment (Table 1).
There was no statistically significant difference
between the mean heart rates of the control, solvent,
and nebivolol groups at the beginning of the study,
whereas the mean heart rate at the end of the study
was significantly lower in the nebivolol group than in
the other groups (P < 0.01).
The mean heart rate in the nebivolol group was
211.01 ± 14.12 beats per minute at the beginning, and
182.85 ± 14.25 beats per minute at the end of the
study, indicating a statistically significant decrease (P
< 0.05). No significant difference was found between
the heart rates prior to and at the end of the study in
the control or solvent groups (Table 1).
Tissue NO levels
The mean NO levels per gram of wet tissue were
17.81 ± 2.55 μmol in the control, 16.26 ± 1.63 μmol

in the solvent, and 23.44 μ 3.18 μmol in the nebivolol
groups (Figure 1). There was no statistically
significant difference between the control and solvent
groups, while the NO levels in the nebivolol group
were significantly higher (P < 0.01) than those of the
other groups.
Immunohistochemical findings
The mean staining scores were 1.85 ± 0.29 in the
control, 1.71 ± 0.16 in the solvent, and 0.85 ± 0.17 in
the nebivolol groups (nebivolol vs. control and
solvent, P < 0.05). No significant difference was found
regarding the endothelin-1 staining density in the
control and solvent groups, while the nebivolol group
had both reduced intimal thickening and reduced
intimal staining (Figure 2A, B, and C).
The PDGF-β staining in the intimal region was
less dense in the nebivolol group than in the control
and solvent groups (Figures 3A, B, and C). The mean
staining scores were 1.56 ± 0.21 in the control group
and 2.00 ± 0.33 in the solvent group, and there was no
significant difference between these values. On the
other hand, the mean staining score for PDGF-β was
0.71 ± 0.19 in the nebivolol group, and the staining
density was significantly reduced as compared with
the other groups (nebivolol vs. control and solvent, P
< 0.05).

Table 1: Mean arterial pressure values, mean heart rate values, and NO levels.
Average Arterial Blood Pressure (mmHg)

Average Heart Rate (beats/min)

Groups

Beginning

End

P
(Beginning End)

Beginning

End

P
(BeginningEnd)

NO
Levels
(μmol)

Control (n = 7)

82.21 ± 3.48

81.57 ± 3.15

NS

209.57 ± 15.37

214.71 ± 13.87

NS

17.81 ± 2.55

Solvent (n = 7)

83.14 ± 3.97

82.71 ± 2.93

NS

211.57 ± 13.57

215.42 ± 11.87

NS

16.26 ± 1.63

Nebivolol (n = 7)

82.57 ± 4.35

62.57 ± 3.86* a

aP < 0.01

211.01 ± 14.12

182.85 ± 14.25* b

b P < 0.01

23.44 ± 3.18

NS

* P < 0.01
(Nebivolol vs. Control)
(Nebivolol vs. Solvent)

NS

* P < 0.01
(Nebivolol vs. Control)
(Nebivolol vs. Solvent)

P (between groups)

** P < 0.01
(Nebivolol group
vs. Control group)
(Nebivolol group vs.
Solvent group)

* P < 0.01 (nebivolol end vs. control end and solvent end); ** P < 0.01 (nebivolol group vs. control and solvent groups);
a
P < 0.01 (nebivolol beginning vs. nebivolol end); b P < 0.01 (nebivolol beginning vs. nebivolol end); NS: Not significant.
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NO (µmol/g wet tissue)

30

Control

Solvent

Nebivolol

25
20

17.81

23.44
*

16.26

15
10
5
0

Figure 1. Tissue NO levels P < 0.01 (nebivolol vs. control and
solvent).

Figure 2A. Histologic section of the aorta of a rabbit from the
control group ([+++] intimal immunostaining for
endothelin-1, ×200).
I: Intima, M: Media, A: Adventitia
iel: internal elastic lamina, eel: external elastic lamina.

Figure 2B. Histologic section of the aorta of a rabbit from the
solvent group ([+++] intimal immunostaining for
endothelin-1, ×200).
I: Intima, M: Media, A: Adventitia
iel: internal elastic lamina, eel: external elastic lamina.

Figure 2C. Histologic section of the aorta of a rabbit from the
nebivolol group ([+] intimal immunostaining for
endothelin-1, ×200).
i: Intima, m: Media, a: Adventitia.

The density of staining for basic FGF in the intimal
region was increased in the control and solvent
groups, while it was significantly decreased in the
nebivolol group (Figures 4A, B, and C). According to
the scoring system, the mean scores were 2.14 ± 0.45
in the control group and 1.85 + 0.37 in the solvent
group, while it was 0.85 ± 0.14 in the nebivolol group.

Discussion

There was no statistically significant difference
between the control and the solvent groups, while the
score was significantly lower in the nebivolol group
(nebivolol vs. control and solvent, P < 0.01).
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In intimal hyperplasia experiments, embolectomy,
neointimal formation after balloon angioplasty
catheters, and induction of tension in the wall are the
most commonly used methods, particularly in rabbits
(20,21). The damage caused to the endothelium by
inflation of the balloon stimulates platelet adhesion
and progressive smooth muscle cell proliferation in
the intima of arteries (5,20). In experimental models,
3 phases have been described in the development of
intimal hyperplasia, including the medial smooth
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Figure 3A. Histologic section of the aorta of a rabbit from the
control group ([++] intimal immunostaining for
PDGF-β, ×200).
iel: internal elastic lamina, eel: external elastic lamina
i: Intima, m: Media, a: Adventitia.

Figure 3B. Histologic section of the aorta of a rabbit from the
solvent group ([++] intimal immunostaining for
PDGF-β, ×200).
iel: internal elastic lamina, eel: external elastic lamina
i: Intima, m: Media, a: Adventitia.

Figure 3C. Histologic section of the aorta of a rabbit from the
nebivolol group ([+] intimal immunostaining for
PDGF-β, ×200).
iel: internal elastic lamina, eel: external elastic lamina
i: Intima, m: Media, a: Adventitia.

Figure 4A. Histologic section of the aorta of a rabbit from the
control group ([+++] intimal immunostaining for
bFGF, ×200).
iel: internal elastic lamina, eel: external elastic lamina
i: Intima, m: Media, a: Adventitia.

Figure 4B. Histologic section of the aorta of a rabbit from the
solvent group ([+++] intimal immunostaining for
bFGF, ×200).
iel: internal elastic lamina, eel: external elastic lamina
i: Intima, m: Media, a: Adventitia.

Figure 4C. Histologic section of the aorta of a rabbit from the
nebivolol group ([+] intimal immunostaining for
bFGF, ×200).
iel: internal elastic lamina, eel: external elastic lamina
i: Intima, m: Media, a: Adventitia
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muscle cell replication observed within the first 3
days, migration of the smooth muscle cells towards
the lumen that continues until the 14th day, and
synthesis of the extracellular matrix that appears by
the 15th day (8). In order to allow development of all
phases, we based our study on histomorphologic
evaluation at the end of a 28-day period.
NO is a crucial modulator of vascular damage.
Indeed, NO has a number of intracellular effects that
lead to vasorelaxation, endothelial regeneration,
reduction of oxidation-sensitive mechanisms,
inhibition of leukocyte chemotaxis, and platelet
adhesion (22,23). Many commonly used drugs carry
out their therapeutic actions through the production
of NO and/or enhancement of NO bioactivity (24,25).
For example, carvedilol, a beta-blocker currently used
in the therapy of hypertension and heart failure, has
been shown to possess a direct scavenging activity on
oxygen radicals with consequent potent antioxidant
properties (26). This agent has been more efficient
than other beta-blockers against oxidation of low
density lipoprotein (LDL) induced by rat vascular
smooth muscle cells (VSMC) and prevented leukocyte
adhesion (27). Carvedilol, but not propranolol, has
been reported to be effective in reducing neutrophil
accumulation in hypercholesterolemic rabbits
following myocardial ischemia (28). Moreover,
carvedilol exerted beneficial effects both on
proliferative and early fatty lesions in cholesterol-fed
rabbits (29) and endothelium dependent dilatation in
patients with coronary heart disease (CHD) (30).
Nebivolol has resulted in a significant reduction of
the atherosclerotic lesions elicited by the elevated
dietary cholesterol and an improvement of the
endothelial function and reduced the enhanced
expression of inflammatory and oxidative damage
markers (macrophages, adhesion molecules, and
oxidative epitopes) (31). The other beta-blocker
demonstrated minor effects on atherosclerotic lesion
formation (32).
It has been demonstrated in experimental studies
that the effective dose of nebivolol for increasing the
NO levels is 2.5 mg/kg (33). We used this dose in our
study. Due to the difficulty of its daily intravenous
administration, and because it is lipophilic and has
been used in hypertensive rats intraperitoneally, we
preferred this route for administration. Traditional
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beta-adrenoceptor antagonists such as nebivolol
reduce preload and afterload due to systemic
vasodilation and improve arterial distensibility (34).
In a dose of 5 mg daily, nebivolol effectively reduces
systolic and diastolic blood pressure over a 24-h
period. During treatment with nebivolol arterial
pressure follows the natural circadian rhythm. It has
been demonstrated in numerous placebo-controlled
studies that exercise tolerance is not reduced during
nebivolol therapy. Chronic administration to patients
with left ventricular dysfunction nebivolol increases
myocardial contractility (34).
In studies conducted by Hamon et al. (19) in the
iliac arteries of rabbits, and by Holm et al. (18) and
Chen et al. (35) in the carotid arteries of rats, orallyadministered L-arginin has been shown to reduce
intimal thickening profoundly. Furthermore, in
another study conducted by Lee et al. (36), it has been
shown that chronic NO inhalation reduces the intimal
thickening that develops following arterial balloon
damage.
ET-1 induces cellular hypertrophy, hyperplasia,
matrix synthesis, and the release of various
chemotactic and growth factors and adhesion
molecules in vitro (37). In various studies it has been
shown that exogenously administered ET-1 increases
neointimal formations in a balloon angioplasty model
in the rat carotid arteries. It has also been reported
that the intimal hyperplasia can be reduced via
administration of endothelin receptor antagonists
(38). In human coronary artery smooth muscle and
endothelial cell cultures, it has been shown that
nebivolol reduces endothelin-1 secretion via reducing
the preproendothelin-1 mRNA levels (39). Nebivolol
increases tissue NO levels, and NO in return reduces
the endothelin-1 levels. Mitsutomi et al. (40) have
shown in vascular endothelium cell cultures that
endogenous NO inhibits endothelin-1 synthesis via
guanylate cyclase/cGMP-dependent mechanisms, and
it has been also shown that exogenous NO has
inhibitory effects on the synthesis of ET-1 in
endothelial cells. The observations made in our study
that the NO levels were higher and ET-1
immunostaining was lower in the group in which
nebivolol was administered support this view.
PDGF is released following the activation of
platelets in response to their adhesion and aggregation
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on the damaged vascular surface (11,12). NO has
been shown to inhibit platelet adhesion and
aggregation. In a study conducted by Provost et al.,
SIN-1, a NO donor, has been shown to inhibit the
mural thrombocyte adhesion to the damaged intimal
region in a swine model of angioplasty. Falciani et al.
(41) have demonstrated that nebivolol inhibits the
aggregation of human platelets, and that this effect is
achieved via increasing the NO synthesis. In a study
conducted by Brehm et al. (39) in cell cultures,
nebivolol has been shown to inhibit the proliferation
of human coronary smooth muscle cells induced by
PDGF. Likewise, the reduced immunostaining for
PDGF-β in the intimal region in the group in which
nebivolol was administered for 30 days as compared
with the dense staining in the control and solvent
groups in our study suggests that nebivolol prevents
platelet adhesion and aggregation via increasing NO
synthesis and indirectly reduces PDGF release (42).
Basic fibroblast growth factor (bFGF) is a complex
growth factor with vasoactive activity. It induces
proliferation of cells and vascular tissues via direct
and indirect mechanisms. Endothelial damage is
required for its proliferative activity on vascular
smooth muscle cells. Edelman et al. (30) have
demonstrated in a study that exogenous bFGF causes
increased intimal thickening only when balloon
damage is induced, and have suggested that the
endothelium acts as a mechanical barrier against the
effects of bFGF. Chen et al. (43) have also

demonstrated that local infusion of exogenous bFGF
increases the development of intimal hyperplasia and
cell proliferation following vascular damage in a study
conducted in endarterectomized carotid arteries of
dogs.
We think that treatment that will reduce the
synthesis or release of bFGF will be effective in
prevention of restenotic processes.
In our reviews of the literature, we have found that
Alfke et al. (44) have reported the in vitro inhibition
of bFGF-induced bovine vascular smooth muscle cell
migration by NO. Moreover, in another in vitro study
(39), nebivolol has been shown to inhibit the bFGFinduced proliferation of human coronary smooth
muscle cells.
In conclusion, balloon catheter damage causes
profound intimal thickening in arteries. Nebivolol
increases the vascular NO release, depresses the
increment of endothelin-1 following vascular damage,
reduces the releases of bFGF and PDFG, both of
which are effective in proliferation and migration of
smooth muscle cells, and as a consequence causes
reduced intimal thickening.
Due to all of these properties, we suggest that
nebivolol may be a helpful agent in preventing the
development of early restenosis following vascular
interventions. However, this topic needs to be
investigated more in further experimental and clinical
studies.
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